摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-{[tert-butyl(dimethyl)silyl]oxy}-2-fluoropropan-1-ol | 1182357-89-6

中文名称
——
中文别名
——
英文名称
3-{[tert-butyl(dimethyl)silyl]oxy}-2-fluoropropan-1-ol
英文别名
3-(tert-Butyldimethylsilanyloxy)-2-fluoropropan-1-ol;3-((Tert-butyldimethylsilyl)oxy)-2-fluoropropan-1-OL;3-[tert-butyl(dimethyl)silyl]oxy-2-fluoropropan-1-ol
3-{[tert-butyl(dimethyl)silyl]oxy}-2-fluoropropan-1-ol化学式
CAS
1182357-89-6
化学式
C9H21FO2Si
mdl
——
分子量
208.348
InChiKey
SGVLKJGGRRBQRK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.34
  • 重原子数:
    13
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-{[tert-butyl(dimethyl)silyl]oxy}-2-fluoropropan-1-ol2,6-二甲基吡啶 、 sodium hydride 作用下, 以 二氯甲烷N,N-二甲基甲酰胺 、 mineral oil 为溶剂, 反应 2.0h, 生成 1-(3-{[tert-butyl(dimethyl)silyl]oxy}-2-fluoropropyl)-4-iodo-1H-pyrazole
    参考文献:
    名称:
    Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer
    摘要:
    c-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes. In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a number of approaches to disrupt aberrant c-Met signaling. Screening efforts identified a unique class of 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1. Subsequent SAR studies led to the development of 81 (MK-2461), a potent inhibitor of c-Met that was efficacious in preclinical animal models of tumor suppression. In addition, biochemical studies and X-ray analysis have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase. This report details the development of 81 and provides a description of its unique biochemical properties.
    DOI:
    10.1021/jm200112k
  • 作为产物:
    描述:
    (3-benzyloxy-2-fluoropropoxy)-tert-butyldimethylsilane 在 Pearlman catalyst 氢气 作用下, 以 甲醇 为溶剂, 20.0 ℃ 、101.33 kPa 条件下, 反应 25.0h, 生成 3-{[tert-butyl(dimethyl)silyl]oxy}-2-fluoropropan-1-ol
    参考文献:
    名称:
    BICYCLOAMINE DERIVATIVES
    摘要:
    由式(I)表示的化合物及其药学上可接受的盐具有出色的钠通道抑制作用,并可用作治疗剂和各种神经痛、神经病、癫痫、失眠、早泄等的镇痛剂。其中Q代表乙烯等,R1、R2和R3代表氢等,X1代表C1-6烷基等,X2代表C1-6烷基等,A1代表5-至6-成员杂环基团等,A2代表C6-14芳基等。
    公开号:
    US20090270369A1
点击查看最新优质反应信息

文献信息

  • Therapeutic Compounds
    申请人:Katz Jason
    公开号:US20110207711A1
    公开(公告)日:2011-08-25
    The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease.
    本发明涉及一种抑制激酶PDK1的吡唑吡啶和咪唑吡啶化合物,因此可用于治疗骨髓增生性疾病或癌症。这些化合物也可用作其他激酶的抑制剂,例如FGFR3、NTRK3、RP-S6K和WEE1。此外,本化合物还具有选择性抑制微管亲和力调节激酶(MARK)的作用,因此可用于治疗或预防阿尔茨海默病。
  • Therapeutic compounds
    申请人:Katz Jason
    公开号:US08455477B2
    公开(公告)日:2013-06-04
    The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease.
    本发明涉及一种吡唑吡啶和咪唑吡啶,它们是激酶PDK1的抑制剂,因此可用于治疗骨髓增生性疾病或癌症。这些化合物还可用作其他激酶的抑制剂,例如FGFR3、NTRK3、RP-S6K和WEE1。此外,本化合物还能选择性地抑制微管亲和力调节激酶(MARK),因此可用于治疗或预防阿尔茨海默病。
  • Discovery of a 5<i>H</i>-Benzo[4,5]cyclohepta[1,2-<i>b</i>]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer
    作者:Jason D. Katz、James P. Jewell、David J. Guerin、Jongwon Lim、Christopher J. Dinsmore、Sujal V. Deshmukh、Bo-Sheng Pan、C. Gary Marshall、Wei Lu、Michael D. Altman、William K. Dahlberg、Lenora Davis、Danielle Falcone、Ana E. Gabarda、Gaozhen Hang、Harold Hatch、Rachael Holmes、Kaiko Kunii、Kevin J. Lumb、Bart Lutterbach、Robert Mathvink、Naim Nazef、Sangita B. Patel、Xianlu Qu、John F. Reilly、Keith W. Rickert、Craig Rosenstein、Stephen M. Soisson、Kerrie B. Spencer、Alexander A. Szewczak、Deborah Walker、Wenxian Wang、Jonathan Young、Qinwen Zeng
    DOI:10.1021/jm200112k
    日期:2011.6.23
    c-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes. In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a number of approaches to disrupt aberrant c-Met signaling. Screening efforts identified a unique class of 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1. Subsequent SAR studies led to the development of 81 (MK-2461), a potent inhibitor of c-Met that was efficacious in preclinical animal models of tumor suppression. In addition, biochemical studies and X-ray analysis have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase. This report details the development of 81 and provides a description of its unique biochemical properties.
  • BICYCLOAMINE DERIVATIVES
    申请人:Ozaki Fumihiro
    公开号:US20090270369A1
    公开(公告)日:2009-10-29
    Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like. wherein Q represents ethylene, etc., R 1 , R 2 and R 3 represent hydrogen, etc., X 1 represents C 1-6 alkylene, etc., X 2 represents C 1-6 alkylene, etc., A 1 represents a 5- to 6-membered heterocyclic group, etc., and A 2 represents C 6-14 aryl, etc.
    由式(I)表示的化合物及其药学上可接受的盐具有出色的钠通道抑制作用,并可用作治疗剂和各种神经痛、神经病、癫痫、失眠、早泄等的镇痛剂。其中Q代表乙烯等,R1、R2和R3代表氢等,X1代表C1-6烷基等,X2代表C1-6烷基等,A1代表5-至6-成员杂环基团等,A2代表C6-14芳基等。
查看更多

同类化合物

(2-溴乙氧基)-特丁基二甲基硅烷 骨化醇杂质DCP 马来酸双(三甲硅烷)酯 顺式-二氯二(二甲基硒醚)铂(II) 顺-N-(1-(2-乙氧基乙基)-3-甲基-4-哌啶基)-N-苯基苯酰胺 降钙素杂质13 降冰片烯基乙基三甲氧基硅烷 降冰片烯基乙基-POSS 间-氨基苯基三甲氧基硅烷 镁,氯[[二甲基(1-甲基乙氧基)甲硅烷基]甲基]- 锑,二溴三丁基- 铷,[三(三甲基甲硅烷基)甲基]- 铂(0)-1,3-二乙烯-1,1,3,3-四甲基二硅氧烷 钾(4-{[二甲基(2-甲基-2-丙基)硅烷基]氧基}-1-丁炔-1-基)(三氟)硼酸酯(1-) 金刚烷基乙基三氯硅烷 辛醛,8-[[(1,1-二甲基乙基)二甲基甲硅烷基]氧代]- 辛甲基-1,4-二氧杂-2,3,5,6-四硅杂环己烷 辛基铵甲烷砷酸盐 辛基衍生化硅胶(C8)ZORBAX?LP100/40C8 辛基硅三醇 辛基甲基二乙氧基硅烷 辛基三甲氧基硅烷 辛基三氯硅烷 辛基(三苯基)硅烷 辛乙基三硅氧烷 路易氏剂-3 路易氏剂-2 路易士剂 试剂3-[Tris(trimethylsiloxy)silyl]propylvinylcarbamate 试剂2-(Trimethylsilyl)cyclopent-2-en-1-one 试剂11-Azidoundecyltriethoxysilane 西甲硅油杂质14 衣康酸二(三甲基硅基)酯 苯胺,4-[2-(三乙氧基甲硅烷基)乙基]- 苯磺酸,羟基-,盐,单钠聚合甲醛,1,3,5-三嗪-2,4,6-三胺和脲 苯甲醇,a-[(三苯代甲硅烷基)甲基]- 苯基二甲基氯硅烷 苯基二甲基乙氧基硅 苯基乙酰氧基三甲基硅烷 苯基三辛基硅烷 苯基三甲氧基硅烷 苯基三乙氧基硅烷 苯基三丁酮肟基硅烷 苯基三(异丙烯氧基)硅烷 苯基三(2,2,2-三氟乙氧基)硅烷 苯基(3-氯丙基)二氯硅烷 苯基(1-哌啶基)甲硫酮 苯乙基三苯基硅烷 苯丙基乙基聚甲基硅氧烷 苯-1,3,5-三基三(三甲基硅烷)